Loading
Life sciences · Observational Study
ClinicalTrials.gov · November 2, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Observational Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07215962). This is a study registration, not published results. Lead sponsor: Bristol-Myers Squibb. Recruitment status: COMPLETED. Study type: OBSERVATIONAL. Enrollment: 300 participants (ACTUAL). Conditions: Non-small Cell Lung Cancer (NSCLC). Interventions: BIOLOGICAL: Nivolumab + ipilimumab; BIOLOGICAL: Nivolumab + ipilimumab + platinum-based chemotherapy; BIOLOGICAL: Immuno-oncology-based therapy (excluding nivolumab-based regimens) with chemotherapy; BIOLOGICAL: Other dual-immuno-oncology therapy with chemotherapy. Primary outcome measures: Incidence of treatment-related adverse events , Baseline; Participant baseline clinical characteristics , Baseline; Time to onset of treatment-related adverse events , Up to 8 years; Number of treatment-related adverse events resolved , Up to 8 years; Number of participants receiving treatment for treatment-related adverse events by drug class , Up to 8 years; Number of participants that discontinued immune-oncology therapy due to treatment-related adverse events , Up to 8 years. Brief summary: The purpose of this study is to assess the treatment-related adverse events and associated healthcare resource use in programmed death ligand 1 (PD-L1) negative individuals diagnosed with advanced/metastatic non-small cell lung cancer (NSCLC) who received first-line therapy